Nuclea Biotechnologies has secured $1 million in a round of equity financing from 10 investors. The Pittsfield, Mass.-based company focuses on the commercialization of cancer and diabetes diagnostic tests, including a blood-based assay that CEO Patrick Muraca said has been clinically tested for monitoring prostate cancer and other uses.
Nuclea obtains $1 million in equity funding round
SmartBrief Job Listings for Health Care
|Senior Director, Biostatistics||
|Compliance and Ethics Director||
Sysmex America, Inc.
|Director, Site Quality Management||
|Palm Springs, CA|